{"record":{"code":"W-01621","indicator":"Debarred / sanctioned abroad × US SEC issuer","class_b":false,"subject":"NVS · SUB · EC · ISSFA","buyer":"","amount":227435.4,"currency":null,"records":3,"found":"2026-10-04","refs":["SICM-093-2022","ocds-5wno2w-RE-ISSFA-2021-012-2803","ocds-5wno2w-RE-ISSFA-2021-022-2803","ocds-5wno2w-CE-20240002570115-2803","2020-06-25","2016-03-23"],"id":"W-01621","html":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01621/","json":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01621/index.json","why":"Indicator “Debarred / sanctioned abroad × US SEC issuer”: subsidiary/issuer «NOVARTIS ECUADOR S.A.» ↔ SEC NVS (CIK 1114448, NOVARTIS AG): 3 non-competitive contracts at the buyer «ISSFA», 227,435 USD (≈ $227,435); one bid, method direct (Catálogo electrónico - Compra directa en el convenio SICM-093-2022, ADQUISICION DE CATALOGO DE MEDICAMENTOS, SELECCIÓN DE PROVEEDORES PARA LA INCORPORACIÓN DE MEDICAMENTOS; OCID ocds-5wno2w-RE-ISSFA-2021-012-2803, ocds-5wno2w-RE-ISSFA-2021-022-2803, ocds-5wno2w-CE-20240002570115-2803; ⚑ REPEAT: already sanctioned SEC by FCPA (2020-06-25 Novartis AG, 2016-03-23 Novartis AG).","facts":[["Company / subject","NVS · SUB · EC · ISSFA",null],["Indicator","Debarred / sanctioned abroad × US SEC issuer",null],["Amount","227,435",null],["Records behind the indicator","3",null],["Found","4 October 2026",null],["Code","W-01621",null],["Reference","SICM-093-2022",null],["Reference","ocds-5wno2w-RE-ISSFA-2021-012-2803",null],["Reference","ocds-5wno2w-RE-ISSFA-2021-022-2803",null],["Reference","ocds-5wno2w-CE-20240002570115-2803",null],["Reference","2020-06-25",null],["Reference","2016-03-23",null]],"summary":"subsidiary/issuer «NOVARTIS ECUADOR S.A.» ↔ SEC NVS (CIK 1114448, NOVARTIS AG): 3 non-competitive contracts at the buyer «ISSFA», 227,435 USD (≈ $227,435); one bid, method direct (Catálogo electrónico - Compra directa en el convenio SICM-093-2022, ADQUISICION DE CATALOGO DE MEDICAMENTOS, SELECCIÓN DE PROVEEDORES PARA LA INCORPORACIÓN DE MEDICAMENTOS; OCID ocds-5wno2w-RE-ISSFA-2021-012-2803, ocds-5wno2w-RE-ISSFA-2021-022-2803, ocds-5wno2w-CE-20240002570115-2803; ⚑ REPEAT: already sanctioned SEC by FCPA (2020-06-25 Novartis AG, 2016-03-23 Novartis AG)","entity":"2b9c709e"},"about":"Indicators computed from public data sets: contracts, payments, registers, trade and sanctions lists. An indicator is a reason to check, not a decision of a public authority.","evidence":[],"row":{"country":"Ecuador","iso2":"EC","part":"Findings","indicator":"Debarred / sanctioned abroad × US SEC issuer","about":"Indicators computed from public data sets: contracts, payments, registers, trade and sanctions lists. An indicator is a reason to check, not a decision of a public authority.","findings":84,"new_today":0,"on_pages":84,"full_list":[],"html":"https://worldwide-corruption.com/database/ecuador/findings/fcpa-pattern/","json":"https://worldwide-corruption.com/database/ecuador/findings/fcpa-pattern/index.json"},"other_records_of_this_company":[],"html":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01621/","json":"https://worldwide-corruption.com/record/ecuador/findings/fcpa-pattern/W-01621/index.json"}